Key result
PPARgamma2 Ala12 variant linked to ~19% lower T2D risk, particularly at lower BMI and in Asia.
Why the study?
Conflicting results have been reported regarding the role of the PPARgamma2 Pro12Ala polymorphism in type 2 diabetes risk, suggesting genetic heterogeneity.
Does the PPARgamma2 Ala12 variant reduce the risk of type 2 diabetes?
Meta-Analysis (n=42,910)
Yes
Does the PPARgamma2 Ala12 variant reduce the risk of type 2 diabetes?
The PPARgamma2 Ala12 variant is associated with a reduced risk of type 2 diabetes, though the protective effect is highly heterogeneous and modulated by BMI and geographic region.
Answers are grounded in this paper and cite their sources.
PPARgamma2 Ala12 should not guide T2D risk assessment; leaves open BMI-modulated genetic effects for prospective validation.
Conflicting results have been reported regarding whether the PPARgamma2 Pro12Ala polymorphism plays a role in the risk of type 2 diabetes (T2D), suggesting genetic heterogeneity. To investigate this issue, a meta-analysis of 41 published and 2 unpublished studies (a total of 42,910 subjects) was conducted. Ala12 carriers had a 19% T2D risk reduction, but this association was highly heterogeneous (p = 0.005). A great proportion (48%) of heterogeneity was explained by the controls' BMI, with risk reduction being greater when BMI was lower. Risk reduction of Ala12 carriers in Asia (35%) was higher than in Europe (15%, p = 0.02) and tended to be higher than in North America (18%, p = 0.10). Difference between Asians and Europeans was no longer significant (p = 0.15) after adjusting for the controls' BMI. Studies from Europe were still heterogeneous (p = 0.02) with risk reduction in Ala12 carriers being progressively smaller (test for trend in the odds ratios, p = 0.02) from Northern (26% reduction, p < 0.0001) to Central (10%, p = 0.04) and Southern (0%, p = 0.94) Europe. In conclusion, in our meta-analysis, the reduced risk of T2D in Ala12 carriers is not homogeneous. It is greater in Asia than in Europe and, among Europeans, it is higher in Northern Europe, barely significant in Central Europe, and nonexistent in Southern Europe.
No takes yet. Share an insight, caveat, or question.
Ludovico et al. (2007) conducted a meta-analysis in Type 2 diabetes (T2D) (n=42,910). PPARgamma2 Pro12Ala polymorphism (Ala12 variant) vs. Non-carriers was evaluated on Type 2 diabetes risk (19% risk reduction). Carriage of the PPARgamma2 Ala12 variant was associated with a 19% reduction in type 2 diabetes risk, with the protective effect being greater in populations with lower BMI and in Asia.
Synapse has enriched 10 related papers. Consider them for comparative context: